CD34 and pancreatic neoplasm: These findings highlight that the differential modulation of CD31+- and CD34+-defined vasculature by PAK1 or PAK4 could be strategically leveraged to optimise chemotherapy and vascular-targeted interventions in pancreatic cancer.